UVADEX 20 MCG
METHOXSALEN : 20 MCG · DIN 02406233 · THERAKOS LLC
Health Canada status: MARKETED
What is UVADEX?
UVADEX 20 MCG contains METHOXSALEN : 20 MCG. It is listed in the Health Canada Drug Product Database under DIN 02406233, held by THERAKOS LLC, supplied as SOLUTION for EXTRACORPOREAL administration. Health Canada currently lists it as marketed, status dated 09-Dec-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is UVADEX used for?
UVADEX (methoxsalen) Sterile Solution is indicated for extracorporeal administration with the THERAKOS CELLEX Photopheresis System in the palliative treatment of the skin manifestations of Cutaneous T-Cell Lymphoma (CTCL) that is unresponsive to other forms of treatment. The indication was authorized based on response rate (25% reduction in skin score maintained for four consecutive weeks) demonstrated in a single-arm phase II study.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02406233 |
|---|---|
| Brand name | UVADEX |
| Generic / active ingredient | METHOXSALEN : 20 MCG |
| Manufacturer | THERAKOS LLC |
| Strength | 20 MCG |
| Dosage form | SOLUTION |
| Route of administration | EXTRACORPOREAL |
| Schedule | Prescription |
| ATC code | D05BA02 METHOXALEN, SYSTEMIC |
| AHFS class | 84:50.06 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 09-Dec-2013 |
| Original market date | 2013-12-09 00:00:00 |
How is it stored and handled?
See 11 STORAGE, STABILITY AND DISPOSAL
How is it supplied?
10 mL vials, cartons of 12 vials
What can be used instead?
Other Canadian products sharing ATC code D05BA02 METHOXALEN, SYSTEMIC. 1 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| OXSORALEN CAP 10MG | 10 MG | CAPSULE | VALEANT CANADA LP / VALEANT CANADA S.E.C. | CANCELLED POST MARKET | DIN 01946374 |
| OXSORALEN-ULTRA CAP 10MG | 10 MG | CAPSULE | VALEANT CANADA LP / VALEANT CANADA S.E.C. | CANCELLED POST MARKET | DIN 00252654 |
| ULTRAMOP CAP 10MG | 10 MG | CAPSULE | CANDERM G.P. | CANCELLED POST MARKET | DIN 00646237 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.